Skip to main content
KyungdongPharm logo

KyungdongPharm — Investor Relations & Filings

Ticker · 011040 ISIN · KR7011040003 KO Manufacturing
Open in API
Filings indexed 303 across all filing types
Latest filing 2026-01-27 Director's Dealing
Country KR South Korea
Listing KO 011040

About KyungdongPharm

https://kdpharma.co.kr

KyungdongPharm is a pharmaceutical company engaged in the development, manufacturing, and distribution of medicines. Since its establishment in 1975, the company has focused on producing a broad portfolio of specialized therapeutic drugs and general pharmaceuticals. Its product lines encompass prescription medicines, with a focus on areas such as liver therapy, and over-the-counter products, including its prominent painkiller brand, 'Geunal-N'. The company also manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates. Utilizing advanced production facilities and proprietary technology, KyungdongPharm is dedicated to developing high-quality medicines supported by clinical research to contribute to public health.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory requirement for directors and major shareholders to disclose their personal share transactions (insider trading). Based on the provided categories, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2026-01-27 Korean
자기주식처분결과보고서
Transaction in Own Shares Classification · 100% confidence The document is a 'Report on the Results of Treasury Stock Disposal' (자기주식처분결과보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the specific disposal of treasury shares related to the issuance of exchangeable bonds. This document is a formal regulatory filing reporting the execution of a previously announced corporate action regarding the company's own shares. Since it reports the actual disposal of treasury shares rather than just an announcement of intent or a general regulatory notice, it falls under the 'Transaction in Own Shares' category.
2025-12-24 Korean
증권발행결과(자율공시)
Capital/Financing Update Classification · 95% confidence The document is a 'Securities Issuance Result' (증권 발행결과) filing from Kyungdong Pharmaceutical. It details the completion of a private placement of exchangeable bonds (사모 교환사채). This falls under the category of capital structure changes and financing activities. According to the provided definitions, 'CAP' (Capital/Financing Update) is the most appropriate category for updates on company fundraising and financing activities.
2025-12-24 Korean
[기재정정]주요사항보고서(교환사채권발행결정)
Capital/Financing Update Classification · 95% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a correction (정정신고) to a previously filed 'Decision to Issue Exchangeable Bonds' (교환사채권 발행결정). It details specific amendments to investment justifications, fund usage, and investor lists. In the context of financial filings, this falls under 'Capital/Financing Update' as it pertains to the issuance of debt instruments (exchangeable bonds) and the associated capital structure changes.
2025-12-22 Korean
[기재정정]주요사항보고서(자기주식처분결정)
Transaction in Own Shares Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding the 'Decision to Dispose of Treasury Shares' (자기주식 처분 결정) and is explicitly labeled as a 'Correction Report' (정정신고). It details the rationale for disposing of treasury shares via exchangeable bonds to fund facility investments (new factory and R&D center). This falls under the category of 'Transaction in Own Shares' (POS) as it pertains to the company's decision to dispose of its own shares.
2025-12-22 Korean
주요사항보고서(교환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange, specifically detailing the decision to issue exchangeable bonds (교환사채권 발행결정). This document outlines the terms of the bond, the use of proceeds for facility investment, and the rationale for choosing this financing method over others. It is a formal regulatory filing regarding capital structure and financing, which falls under the 'Capital/Financing Update' category.
2025-12-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.